Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

Gopila Gupta, May Chiu, Eshrak Al-Shaibani, Maria Agustina Perusini, Josephine Lucero, Daniela Zackova, Ivana Jeziskova, Anezka Kvetkova, Tomas Jurcek, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Jiri Mayer, Jessie Medeiros, Sagi Abelson, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 4531.

https://doi.org/10.1182/blood-2023-189827

Published: 2023

Journal Articles

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Ho-Jae Han, Eun-Ju Park, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6336.

https://doi.org/10.1182/blood-2023-185440

Published: 2023

Journal Articles

Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality

Muzaffar Bhatti, Taehyung Kim, Jenny Warrington, Amirthagowri Ambalavanan, Sarah Zarabi, Anthea Travas, Jaeyoon John Kim, Danielle Pyne, Troy Ketela, Andrea Arruda, Mark D. Minden, Armand Keating, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 6042.

https://doi.org/10.1182/blood-2023-185149

Published: 2023

Journal Articles

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

Blood (2023) 142 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2023-189797

Published: 2023

Journal Articles

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Ayman Sayyed, Hyewon Lee, Taehyung Simon Kim, Jaeyoon John Kim, Danielle Pyne, Nathali Kaushansky, Yardena Brilon, Noa Chapal-Ilani, Tamir Biezuner, Liran I. Shlush, Jan Storek, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2023-191191

Published: 2023

Journal Articles

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Ho-Jae Han, Jaeyoon John Kim, Danielle Pyne, Anthea Travas, Amirthagowri Ambalavanan, Shinya Kimura, Michael W. Deininger, Jong-Won Kim, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2023-188135

Published: 2023

NARROW

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Email alerts

ASH Publications

American Society of Hematology

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia

Presence of Recurrent Somatic Mutations in Mesenchymal Stromal Cell Fractions Isolated from Acute Myeloid Leukemia As an Evidence of Clonality

Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

The Presence of Somatic Mutation in Donor Does Not Affect Long-Term Outcomes in 339 Patients Following Allogeneic Hematopoietic Stem Cell Transplantation Using Uniform Fludarabine/Busulfan Myeloablative Conditioning and Cyclosporine/Methotrexate and ATG Gvhd Prophylaxis

Asciminib Enhances Its Treatment Efficacy Synergistically in the Treatment of Chronic Myeloid Leukemia Harboring ABL1 Kinase Domain Mutation When Combined with a Reduced Dose of Ponatinib, Dasatinib, or Bosutinib, but Not with Nilotinib or Imatinib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only